Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Immunotherapy embodies any approach that manipulates the immune system for therapeutic benefit. In this regard, various clinical trials have employed direct vaccination with patient-specific dendritic cells or adoptive T cell therapy to target highly aggressive tumors. Both modalities have demonstrated great specificity, an advantage that is unmatched by other treatment strategies. However, their full potential has yet to be realized. Areas covered: In this review, we provide an overview of chemokines in pathogen and anti-tumor immune responses and discuss further improving immunotherapies by arming particular chemokine axes. Expert commentary: The chemokine macrophage inflammatory protein-1 alpha (MIP-1α, CCL3) has emerged as a potent activator of both innate and adaptive responses. Specifically, CCL3 plays a critical role in recruiting distinct immune phenotypes to intratumoral sites, is a pivotal player in regulating lymph node homing of dendritic cell subsets, and induces antigen-specific T cell responses. The recent breadth of literature outlines the various interactions of CCL3 with these cellular subsets, which have now served as a basis for immunotherapeutic translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“tion, exert immunosuppressive pathways, regulate angiogenesis, and facilitate metastatic spread [97].”
BackgroundCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“CTLA-4, a receptor constitutively expressed on T-regulatory cells (TRegs) and upregulated during activation of effector T-cells, mediates downregulation of the immunologic response in activated lymphocytes [77,78].”
BackgroundThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions
Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Kiafard, Z., Zwirner, J., Blankenstein, T., Henning, G., & Förster, R. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.014 · Cited by 1,086 · cited 1×
“It has been shown that CCR7-deficient DCs fail to migrate effectively from the skin into lymphatics [6,108], a biologic event that is critical for”
BackgroundInterstitial dendritic cell guidance by haptotactic chemokine gradients
Weber, M., Hauschild, R., Schwarz, J., Moussion, C., de Vries, I., Legler, D. F., Luther, S. A., Bollenbach, T., & Sixt, M. (2013) · Science · doi:10.1126/science.1228456 · Cited by 555
Ransohoff, R. M., Hamilton, T. A., Tani, M., Stoler, M. H., Shick, H. E., Major, J. A., Estes, M. L., Thomas, D. M., & Tuohy, V. K. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.6.8472896 · Cited by 496
Gao, J.-L., Wynn, T. A., Chang, Y., Lee, E. J., Broxmeyer, H. E., Cooper, S., Tiffany, H. L., Westphal, H., Kwon-Chung, J., & Murphy, P. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.11.1959 · Cited by 441 · cited 1×
“systems, CCL3 effectively recruits high amounts of mononuclear cells [47,48].”
BackgroundChemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398 · cited 1×
“Preclinical studies to date have implemented CCL3 as a monotherapy or combinatorial adjuvant to induce both tumor regression and immunity to tumor rechallenge [89] (Table 4).”
BackgroundGene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy
Gough, M., Crittenden, M., Thanarajasingam, U., Sanchez-Perez, L., Thompson, J., Jevremovic, D., & Vile, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5766 · Cited by 60 · cited 1×
“Human Ovarian carcinoma (CHO) BALB/c Neutrophils, granulocytes Reduced tumorigenicity [90] Human, Mouse Colon adenocarcinoma (C26) BALB/c Macrophages, granulocytes Reduced tumorigenicity [91] Mouse Melanoma (B16F10-OVA, B16-CCL3) C57BL/6 Adoptively transferred antigen-specific CD8 T cell (OT-I), endogenous CD8 T cells…”
Background
Cited by
Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., & Baranowska-Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207619 · Cited by 373
The role of chemokines and chemokine receptors in multiple sclerosis
Cui, L.-Y., Chu, S.-F., & Chen, N.-H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106314 · Cited by 135
Martins, T. A., Kaymak, D., Tatari, N., Gerster, F., Hogan, S., Ritz, M.-F., Sabatino, V., Wieboldt, R., Bartoszek, E. M., McDaid, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54129-w · Cited by 54
D’Souza, S. S., Zhang, Y., Bailey, J. T., Fung, I. T. H., Kuentzel, M. L., Chittur, S. V., & Yang, Q. (2021) · Aging Cell · doi:10.1111/acel.13470 · Cited by 32
Metadata
- Authors
- Schaller, T. H., Batich, K. A., Suryadevara, C. M., Desai, R., & Sampson, J. H.
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2017-10-05
- Volume
- 13
- Issue
- 11
- Pages
- 1049-1060
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W2763449827
- Cited by
- 147
- References
- 10
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. https://app.cochat.ai/papers/10.1080/1744666x.2017.1384313
- The paper
- Schaller, T. H., Batich, K. A., Suryadevara, C. M., Desai, R., & Sampson, J. H. (2017). Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. Expert Review of Clinical Immunology. https://doi.org/10.1080/1744666x.2017.1384313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.